TP53 mutation
TP53-mutated AML and MDS-EB do not differ with respect to their clinical and molecular characteristics or survival outcomes.
Study finds BM CH was present in nearly two-thirds of BPDCN patients and particularly prevalent in elderly patients.
A phase III trial of magrolimab plus azacitidine versus standard of care in TP53-mutated AML is currently ongoing.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.